The Keytruda Patent Cliff: Pricing Dynamics Following Biosimilar Competition
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
$2995
As a blockbuster therapy in immuno-oncology, Keytruda has undoubtedly established itself as one of the most clinical and commercially successful medicines across the global biopharmaceutical landscape. Its upcoming loss of exclusivity therefore represents one of the most consequential and prominent events in the global oncology market, with far-reaching pricing implications.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
See what our customers are saying
Related reports
View more Oncology reports
New
New
New